

निविदा से संबंधित तकनीकी मूल्यांकन समिति की बैठक की कार्यवाही

निविदा संख्या: BMSIC/DRUGS/17-08

दिनांक: 28-02-2018

समय: 11:00 बजे पूर्वाह्न

स्थान : बिहार चिकित्सा सेवाएँ एवं आधारभूत संरचना निगम लिमिटेड का सभागार

उपस्थिति-पंजी के अनुसार

बिहार चिकित्सा सेवाएँ एवं आधारभूत संरचना निगम लिमिटेड द्वारा विभिन्न प्रकार के औषधियों का दर अनुबन्ध करने हेतु दिनांक 20/09/2017 को निविदा संख्या BMSIC/DRUGS/17-08 का प्रकाशन विभिन्न समाचार पत्रों में किया गया। निविदा सूचना में उल्लेखित कार्यक्रम के अनुसार दिनांक 05/10/2017 को इच्छुक निविदादाताओं की निविदा पूर्व (Pre-Bid) बैठक आयोजित की गई। Pre-Bid बैठक के आलोक में कतिपय संशोधनों को सम्मिलित करते हुए ई-निविदा के माध्यम से निविदा जमा करने की अंतिम तिथि 04/11/2017 तक विस्तारित की गई।


2. निविदा जमा करने की अंतिम तिथि तक कुल 28 निविदादाताओं की निविदाएँ ई-निविदा के माध्यम से प्राप्त हुई। सभी प्राप्त तकनीकी निविदाओं का मूल्यांकन प्रपत्र BMSICL में प्रतिनियुक्त औषधि निरीक्षकों द्वारा तैयार कर निगम के वेबसाइट पर प्रकाशित किया गया, जिसके विरुद्ध निविदादाताओं से स्पष्टीकरण एवं प्राप्त संलग्न कागजातों की जाँच कर प्रतिनियुक्त औषधि निरीक्षकों की टीम द्वारा तुलनात्मक विवरणी तैयार की गई। दिनांक 20.02.2018 को आयोजित बैठक में उक्त तुलनात्मक विवरणी की समीक्षा के क्रम में पाया गया कि कतिपय निविदादाताओं द्वारा कोई स्पष्टीकरण नहीं दिया गया है। अतः सभी निविदादाताओं को एक और अंतिम अवसर प्रदान करते हुए ई0 मेल के माध्यम से सूचित करने का निर्णय लिया गया।

3. ई-मेल के माध्यम से सूचित करने के उपरांत समय सीमा के अंदर समर्पित कागजातों, मूल्यांकन प्रपत्र तथा तुलनात्मक विवरणी की समीक्षा की गई। समीक्षोपरान्त निम्नांकित निविदादाता संस्थानों की निविदा उनके नाम के सामने अंकित औषधियों के लिए तकनीकी रूप से योग्य पाई गई :-

S. N.	Name of Bidder	Qualified Technically for following drugs (NIT S.N.)
1.	M/s Akum Drugs & Pharmaceuticals Ltd.	NIT S N.-1 (Aceclofenac Tablets IP 100mg), NIT S N.-4 (Amoxycillin and Potassium Clavulanate Inj. IP 1.2gm/vial), NIT S N.-5 (Ceftriaxone Inj. IP 1g), NIT S N.-8 (Cefixime Tablets IP 200 mg), NIT S N.-9 (Fluconazole Tablets IP 150 mg), NIT S N.-41 (Paracetamol Tablets IP 500 mg) NIT S N.-47 (Atropine Injection IP 600 600µg/ml Amp.) & NIT S N.-53 (Ofloxacin Ophthalmic solution IP 0.3%).



2.	M/s ANG Life Science India Ltd.	NIT S.N.-5 (Ceftriaxone inj. IP 1g vial) , NIT S N.-30 (Hydrocortisone sodium succinate inj. IP 100 mg), NIT S N.-38 (Artesunate Inj. 60 mg vial).
3.	M/s Arion Healthcare	NIT S.N.- 1(Aceclofenac Tablet IP 100 mg), NIT S N.-3 (Amikacin inj. IP 500 mg/2ml vial) NIT S N.-5 (Ceftriaxone Inj. IP 1g), NIT S N.-8 (Cefixime Tablets 200 mg IP), NIT S N.-9 (Fluconazole Tablets IP 150 mg), NIT S N.-30 (Hydrocortisone sodium succinate inj. IP 100 mg), NIT S N.-34 (Ceftriaxone + Salbactam inj. 500 mg+250mg vial), NIT S N.-38 (Artesunate Inj. 60mg) NIT S N.- 41(Paracetamol Tablets IP 500 mg), & NIT S N.-53 (Ofloxacin Ophthalmic solution IP 0.3%w/w).
4.	M/s Concept Pharmaceuticals Pvt. Ltd	NIT S N.-3 (Amikacin inj. IP 500 mg/2ml vial) & NIT S N.-5 (Ceftriaxone Inj. IP 1g),
5.	M/s Daffodills Pharmaceuticals Ltd	NIT S.N.-10 (Metronidazole Tablets IP 400 mg), & NIT S N.-47 (Atropine Injection IP 600 600µg/ml Amp.) (Regarding pending CBI enquiry against the Ex-director, instruction from the higher Authorities need to be taken report before taking any decision.)
6.	M/s Inven Pharmaceuticals Pvt. Ltd.	NIT S.N.- 13(Compound sodium Lactate Inj. IP) (Ringer Lactate, Flow, Fill & seal process) 500 ml, NIT S N.-14 (Sodium chloride and Dextrose Inj. (DNS), Flow, Fill & seal Process) 500 ml & NIT S N.-15. Sodium Chloride Injection IP (Normal Saline) 500 ml.
7.	M/s La-Chemico Pvt. Ltd.	NIT S.N.-9 (Fluconazole Tab. IP 150 mg), NIT S N.-10 (Metronidazole Tab. IP 400 mg), NIT S N.-11 (Oral Rehydration Salts IP 20.5gm/sachet), NIT S N.-41(Paracetamol Tab. IP 500 mg), NIT S N.-51 (Co-Trimoxazole (Trimethoprim and Sulphamethoxazole Tablet IP 40 mg+ 200 mg) .
8.	M/s Nestor Pharmaceuticals Ltd.	NIT S. N.-8 (Cefixime Tab. IP 200mg), NIT S N.-10 (Metronidazole Tab. IP 400 mg), NIT S N.-11 (Oral Redehydration Salts IP 20.5 gm/sachet),



		NIT S N-41 (Paracetamol Tablet IP 500mg), NIT S N.-51 (Co-Trimoxazole (Trimethoprim and Sulphamethoxazole Tab. IP 40 mg + 200mg).
9.	M/s Ornate Labs Pvt. Ltd.	NIT S. N.-10 (Metronidazole Tab. IP 400 mg).
10.	M/s Otsuka Pharmaceuticals India Pvt. Ltd.	NIT S.N.-13 (Compound Sodium Lactate Inj. IP 500 ml), NIT S N.-14 (0.9 % w/v Sodium chloride and 5 % w/v Dextrose Inj. IP 500 ml, (DNS) & NIT S N.-15. Sodium Chloride Injection IP (Normal Saline) 500 ml.
11.	M/s Ratnamani Healthcare Pvt. Ltd.	NIT S.N.-8 (Cefixime Tablets IP 200 mg. NIT S N.-11 (Oral Rehydration Salts IP 20.5gm/sachet),
12.	M/s Unicare India Ltd.	NIT S.N.-1 (Aceclofenac Tablets IP 100 mg), NIT S N 9 (Fluconazole Tab. IP 150 mg), NIT S N.-10 (Metronidazole Tab. IP 400 mg), NIT S N.- 11 (Oral Rehydration Salts IP 20.5 gm/sachet), NIT S N.-41 (Paracetamol Tablet IP 500mg).
13.	M/s Vivek Pharmachem (India) Ltd.	NIT S.N.-4 (Amoxycillin and Potassium Clavulanate Inj. IP 1.2gm) , NIT S N.- 5 (Ceftriaxone Inj. IP 1g), NIT S N.-8 (Cefixime Tab. IP 200mg), NIT S N.-10 (Metronidazole Tab. IP 400 mg), NIT S N.-30 (Hydrocortisone Sodium succinate inj. IP 100 mg), NIT S N.-34 (Ceftriaxone + Sulbactam Inj. 500mg+250mg).

ii) उपर्युक्त निविदादाता संस्थानों की वित्तीय निविदा खोले जाने की अनुशंसा करने का निर्णय लिया गया, बशर्ते कि वे भौतिक सत्यापन के पश्चात पूर्णरूपेण तकनीकी रूप से योग्य पाये जाये।

4. अंतिम अवसर प्रदान करने के उपरान्त भी निविदा आमंत्रण सूचना की निविदा शर्त के अनुरूप जिन निविदादाताओं द्वारा निविदा के साथ वांछित कागजात जमा नहीं किया गया अथवा निविदा की Basic Eligibility Criteria को पूर्ण नहीं किया गया वैसे निम्नांकित निविदादाता संस्थानों को/ उनके Quoted Products को उनके नाम के सामने अंकित कारणों से तकनीकी रूप से अयोग्य घोषित करने की अनुशंसा करने का निर्णय लिया गया :-




S. N.	Name of Bidder	Disqualified Technically on the following grounds
1.	M/s Albert David Ltd.	The Firm is disqualified technically as :- 1. Manufacturing license in FORM 28-D not submitted for quoted product at NIT S.N-13 & 15 which results in Non compliance of clause-3(f). 2. For NIT S N-19 Maximum production capacity certificate is not submitted and product approval in Brand Name which results in Non compliance of clause-3(k) & 3(f).
2.	M/s Arion Healthcare	The firm is disqualified technically for the quoted product as :- 1. The Product approval for NIT S.N.-19 is not three years old which results in Non compliance of clause-3(f). 2. NIT S.N.-52 specification is Gamma Benzene Hexachloride and quoted product is Gamma Benzene Hexachloride along with Cetrimide. Which results in Non compliance of clause-3(f) & 2(b).
3.	M/s Bal Pharma Ltd	The Firm is disqualified technically as :- 1. The bidding firm has not submitted MOA & AOA, Which results in Non compliance of clause- 3(c). 2. Power of attorney has been sub-delegated, which results in Non compliance of clause- 3(e). 3. Manufacturing & marketing certificate is not submitted for the product mentioned at NIT S.N.- 1 & 10 which results in Non compliance of clause-3(f).
4.	M/s Bharat Parenterals Ltd.	The Firm is disqualified technically as :- 1. Memorandum of Association & Article of Association is not submitted which results in Non-Compliance of 3(c) .
5.	M/s Bochem Healthcare pvt. Ltd.	The Firm is disqualified technically as the company was blacklisted at the time of submission of tender which results in Non compliance of clause-3(n).




6.	M/s Concept Pharmaceuticals Pvt Ltd.	<p>The firm is disqualified technically for the quoted product as :-</p> <p>1. NIT S N-41-Paracetamol Tablet IP 500 mg as draft copy of manufacturing and marketing certificate is submitted which results in Non compliance of clause-3(f).</p>
7.	M/s Daffodills Pharmaceuticals Ltd.	<p>The firm is disqualified technically for the quoted product as :-</p> <p>1. NIT S.N-5 (Ceftriaxone inj. IP 1g vial) as the product approval is for veterinary use which results in Non compliance of clause-3(f).</p> <p>2. NIT S N- 30 (Hydrocortisone sodium succinate inj. IP 100 mg) pack size of quoted product is 5 ml whereas NIT specifications is 20ml Vial which results in Non compliance of clause-2(b) & 3 (f).</p> <p>(Regarding pending CBI enquiry against the Ex-director, instruction from the higher Authorities need to be taken report before taking any decision.)</p>
8.	M/s D.M. Pharma	<p>The firm is disqualified technically for the quoted product as :-</p> <p>1. Bidder name is mentioned as M/s Saar Biotech in annexure III which results in Non compliance of clause-3(o).</p> <p>2 Approved product list with Brand name and not valid till the date of submission of tender which results in Non compliance of clause-3(f), & 2(b).</p>
9.	M/s J.B Chemicals & Pharmaceuticals Ltd.	<p>The Firm is disqualified technically as :-</p> <p>1. The Memorandum and Articles of Association of the bidder firm is not submitted which results in Non compliance of Clause- 3(c).</p> <p>2. The Manufacturing licence in Form 25 & 28 is not submitted which results in Non compliance of Clause- 3(f).</p>



10.	M/s Kwaliti Pharmaceuticals Ltd.	The Firm is disqualified technically as: 1.The bidding firm was blacklisted at the time of date of submission of Tender which results in Non compliance of Clause-3 (n).
11.	M/s Modern Laboratories	The firm is disqualified technically as it was blacklisted on the date of submission of the tender which results in Non compliance of clause-3(n).
12.	M/s Ornate Labs Pvt. Ltd.	The Firm is disqualified technically for quoted product as :- 1.For NIT S.No.-8 (Cefixime Tab. IP 200 mg), which is not in IP which results in Non compliance of clause-3(f) & 2(b). 2. For NIT S.N.- 41 (Paracetamol Tablet IP 500mg) has been approved with Brand name which results in Non compliance of clause-3(f) & 2(b).
13.	M/s Ravian Lifescience Pvt. Ltd.	The firm is disqualified technically as;- 1.The firm has not mentioned Name of Subscribers and date of preparation of MOA & AOA which results in Non compliance of clause-3(c). 2. Quoted products in their approved product list is not highlighted by the bidder as per Clause 3(f). 3.The Firm has submitted modified Annexure V which does not match with NIT Annexure V which is manipulation with Tender document which results in Non compliance of clause-3(d).
14.	M/s Rusan Pharmaceuticals Ltd.	The Firm is disqualified technically as :- 1. Approved product list is for Yurekha Labs for NIT S.N.-23 (Bupivacaine Inj. Heavy (bupivacaine 5mg+ Dextrose Monohydrate 80mg/ml) 4ml) which results in Non-Compliance of Clause 5(a). 2. As Latest Non Conviction certificate is valid upto 30.09.2017 while date of submission of



		online bids is 21.10.2017 which results in Non compliance of clause-3(i).
15.	M/s Shamshree Life science Ltd.	The firm is disqualified technically as it has not submitted Non Conviction certificate and bidder information not submitted which results in Non Compliance of Clause 3 (i) & 3 (d).
16.	M/s Syncom Healthcare Ltd.	The firm is disqualified technically as attached product approval list date is after date of submission of tender which results in Non Compliance of Clause 3 (f).
17.	M/s Themis Medicare Ltd.	The Firm is disqualified technically as :- 1. For NIT S.N.- 12 (Pentazocine Inj. IP 30 mg/ml) three years of manufacturing not completed which results in Non-Compliance of 3(f). 2. For NIT SN- 22 (Bupivacaine Inj. IP (Bupivacaine hydrochloride inj. IP) 25mg/10ml) quoted product is 50 mg/20ml , hence pack size is different which results in Non-Compliance of 2(b) & 3(f).
18.	M/s Unicure India Ltd.	The Firm is disqualified technically as :- 1. For NIT S.N.-8 (Cefixime Tablets IP 200mg) as three years old manufacturing license with IP monograph not completed which results in Non-Compliance of 3(f). 2. For NIT S.N.-31 is Sodium Valporate Tablets IP 200mg where as quoted product is Gastro resistant which results in Non-Compliance of 3(f) & 2 (b).
19.	M/s Verve Human care Laboratories.	The Firm is disqualified technically as :- 1. For NIT S.N.- 7 product approval is with brand name in FORM 28 B and approval with generic name in FORM 28 in place of FORM 28B which results in Non-Compliance of Clause-3(f). 2. For NIT S.N-23 requirement is Bupivacaine 5mg+ Dextrose Monohydrate 80mg/ml while quoted product is Bupivacaine 5mg+ Glucose



		Monohydrate 80mg/ml which results in Non compliance of clause-2(b) &3(f). 3. For NIT S N -39 product approval is less than three years with IP specification which results in Non compliance of clause-2(b) &3(f).
20.	M/s Vivek Pharmachem (India) Ltd.	The firm is disqualified technically for NIT S.No.-42 (Misoprostol Tablets IP 200µg) as three year old manufacturing license not completed which results in Non-Compliance of 3(f).
21.	M/s Zest Pharma	The firm is disqualified technically as approved product list is signed on 05-08-2017 and also proprietor name in license certificate and renewal certificate mismatch which results in Non Compliance of Clause 3 (f) & 3(c).

5. निम्नांकित औषधियों के लिए प्राप्त दो या दो से अधिक निविदाओं के तकनीकी मूल्यांकन के पश्चात वित्तीय मूल्यांकन हेतु एक निविदा ही शेष रह गई है, जिसकी विवरणी निम्न प्रकार है:-

S. N.	Name of Bidder	Single Tender
1.	M/s Arion Healthcare	NIT S N.-33 (Ampicillin + Cloxacillin inj. 500 mg + 500mg),
2.	M/s Daffodills Pharmaceuticals Ltd.	NIT S.N.-44 (Etophylline+ Theiphylline Inj. 169.4 mg + 50.6mg /2 ml). (Regarding pending CBI enquiry against the Ex-director, instruction from the higher Authorities need to be taken report before taking any decision.)
3.	M/s La-Chemico Pvt. Ltd.	NIT S.N.-31 (Sodium Valproate Tablets. IP 200 mg)
4.	M/s Themis Medicare Ltd.	NIT S.N.-7 (Ketamine Hydrochloride Inj. IP 50 mg/ml), NIT S N.-23 (Bupivacaine Inj. Heavy (bupivacaine 5mg+ Dextrose Monohydrate 80mg/ml) 4ml & NIT S N.27 (Lignocaine Hydrochloride and Adrenaline Bitartrate Inj. IP 30ml vial).



5.	M/s Unicare India Ltd.	NIT S.N.- 18 (Norethisterone Tab. IP 5mg), NIT S N.-20 (Fluoxetine Hydrochloride capsule IP 20 mg), NIT S N.-21 (Etophylline+Theophylline Tablets 77 mg+23mg), NIT S N.-52 (Gamma Benzene Hexachloride Lotion).
6.	M/s Vivek Pharmachem (India) Ltd.	NIT S N- 19 (Ciprofloxacin Eye Drops IP) 0.3% w/v) & NIT S N.- 36 (Piperacillin + Tazobactam inj. 2gm+250 mg)

(ii) निम्नांकित औषधियों के लिए एकल निविदा प्राप्त हुई जिसके कारण तकनीकी मूल्यांकन के पश्चात वित्तीय मूल्यांकन हेतु एक निविदा ही शेष रह गई है, जिसकी विवरणी निम्न प्रकार है:-

1.	M/s Unicare India Ltd.	NIT S.N.- 18 (Norethisterone Tab. IP 5mg),
----	------------------------	--

अतः उपर्युक्त वित्तीय मूल्यांकन हेतु शेष एकल निविदा की औषधियों हेतु पुनः निविदा आमंत्रित करने का सर्वसम्मत निर्णय लिया गया।

6. अंत में धन्यवाद ज्ञापन के साथ बैठक की कार्यवाही समाप्त की गई।

28/02/18
राज्य औषधि नियंत्रक,
बिहार

28.2.18
(सुधीर कुमार)
महाप्रबंधक (अधिप्राप्ति),
बी.एम.एस.आई.सी.एल,
बिहार

28/2/18
(खालिद अरशदी)
प्रशासी पदाधिकारी-सह-प्रभारी प्रोक्योरमेंट
राज्य स्वास्थ्य समिति, बिहार

28/2/18
(सच्चिदानन्द चौधरी)
विशेष-सचिव, स्वास्थ्य विभाग,
बिहार

28/2/18
(डॉ० आर० डी० रंजन)
निदेशक प्रमुख,
स्वास्थ्य सेवाएँ, बिहार

